GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (STU:K6S) » Definitions » Total Tax Payable

Mira Pharmaceuticals (STU:K6S) Total Tax Payable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals Total Tax Payable?

Mira Pharmaceuticals's Total Tax Payable for the quarter that ended in Sep. 2024 was €0.00 Mil.


Mira Pharmaceuticals Total Tax Payable Historical Data

The historical data trend for Mira Pharmaceuticals's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Total Tax Payable Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Total Tax Payable
- - -

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mira Pharmaceuticals Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Mira Pharmaceuticals Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Mira Pharmaceuticals Headlines

No Headlines